A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is
non-inferior to that of standard therapy CTX through analyzing overall remission rate after
treatment.